再鼎醫藥-SB(09688.HK):全面包銷發售美國預託股份 4月21日起復牌
格隆匯 4 月 21日丨再鼎醫藥-SB(09688.HK)發佈公吿,2021年4月20日(美國東部時間),公司向美國證交會提交8-K表格,宣佈於美國發售477.6萬股美國預託股份的定價為每股美國預託股份150.00美元,而500萬股普通股的定價為每股普通股1,164.20港元。將予發行的美國預託股份數目佔(i)截至2021年2月26日的60,078,450股發行在外美國預託股份約7.95%;及(ii)經發售擴大的美國預託股份約7.36%(假設可購買最多額外15%的美國預託股份的選擇權尚未行使)。
公司估計是次發售所得款項淨額將約為7.1543億美元(或倘包銷商悉數行使其購買額外美國預託股份的選擇權,則為8.1805億美元)。公司計劃將是次發售所得款項淨額主要用作增加業務及企業發展活動、推進多種候選藥物的臨牀開發、拓展公司的商業化工作,及用於營運資金及其他一般企業用途。
其中,目前公司預期是次發售所得款項淨額的用途如下:約30%的所得款項淨額撥資新業務及企業發展以及授權機會;約30%的所得款項淨額用作完成臨牀試驗及推進新候選藥物;約20%的所得款項淨額用作拓展公司的商業化工作;約15%的所得款項淨額用作提升公司的全球產品管線;及約5%的所得款項淨額用作營運資金及其他一般企業用途。公司股份已自2021年4月20日上午九時正起於香港聯交所暫停買賣,以待刊發本公吿。公司已向香港聯交所申請公司股份自2021年4月21日上午九時正(香港時間)起於香港聯交所恢復買賣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.